Jeffrey K. Bailey

Dr. Jeffrey K. Bailey

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2023 in Ophthalmology
Verified
Journal Article
Closed access
MHMark Humayun
Mark Humayun
DCDennis O. Clegg
Dennis O. Clegg
MDMargot S. Dayan
Margot S. Dayan
AKAmir H. Kashani
Amir H. Kashani
FRFiras M. Rahhal
Firas M. Rahhal
JLJane S. Lebkowski
Jane S. Lebkowski

21 May 2009 in Blood
Verified
Journal Article
Open access
PDF file
MMMichael D. Milsom
Michael D. Milsom
BSBernhard Schiedlmeier
Bernhard Schiedlmeier
JBJeffrey K. Bailey
Jeffrey K. Bailey
MKMi-Ok Kim
Mi-Ok Kim
DLDandan Li
Dandan Li
DWDavid A. Williams
David A. Williams
Ectopic delivery of HOXB4 elicits the expansion of engrafting hematopoietic stem cells (HSCs). We hypothesized that inhibition of tumor necrosis factor-α (TNF-α) signaling may be central to the self-renewal signature of HOXB4. Because HSCs derived from Fanconi anemia (FA) knockout mice are hypersensitive to TNF-α, we studied Fancc−/− HSCs to determine the physiologic effects of HOXB4 on TNF-α sensitivity and the relationship of these effects to the engraftment defect of FA HSCs. Overexpression of HOXB4 reversed the in vitro hypersensitivity to TNF-α of Fancc−/− HSCs and progenitors (P) and partially rescued the engraftment defect of these cells. Coexpression of HOXB4 and the correcting FA-C protein resulted in full correction compared with wild-type (WT) HSCs. Ectopic expression of HOXB4 resulted in a reduction in both apoptosis and reactive oxygen species in Fancc−/− but not WT HSC/P. HOXB4 overexpression was also associated with a significant reduction in surface expression of TNF-α receptors on Fancc−/− HSC/P. Finally, enhanced engraftment was seen even when HOXB4 was expressed in a time-limited fashion during in vivo reconstitution. Thus, the HOXB4 engraftment signature may be related to its effects on TNF-α signaling, and this pathway may be a molecular target for timed pharmacologic manipulation of HSC during reconstitution.

4 July 2022 in Bioengineering
Verified
Journal Article
Open access
PDF file
MFMohamed Faynus
Mohamed Faynus
JBJeffrey K. Bailey
Jeffrey K. Bailey
BPBritney O. Pennington
Britney O. Pennington
MKMika Katsura
Mika Katsura
DPDuncan A. Proctor
Duncan A. Proctor
DCDennis O. Clegg
Dennis O. Clegg
Dry age-related macular degeneration (AMD) is estimated to impact nearly 300 million individuals globally by 2040. While no treatment options are currently available, multiple clinical trials investigating retinal pigmented epithelial cells derived from human pluripotent stem cells (hPSC-RPE) as a cellular replacement therapeutic are currently underway. It has been estimated that a production capacity of >109 RPE cells annually would be required to treat the afflicted population, but current manufacturing protocols are limited, being labor-intensive and time-consuming. Microcarrier technology has enabled high-density propagation of many adherent mammalian cell types via monolayer culture on surfaces of uM-diameter matrix spheres; however, few studies have explored microcarrier-based culture of RPE cells. Here, we provide an approach to the growth, maturation, and differentiation of hPSC-RPE cells on Cytodex 1 (C1) and Cytodex 3 (C3) microcarriers. We demonstrate that hPSC-RPE cells adhere to microcarriers coated with Matrigel, vitronectin or collagen, and mature in vitro to exhibit characteristic epithelial cell morphology and pigmentation. Microcarrier-grown hPSC-RPE cells (mcRPE) are viable; metabolically active; express RPE signature genes including BEST1, RPE65, TYRP1, and PMEL17; secrete the trophic factors PEDF and VEGF; and demonstrate phagocytosis of photoreceptor outer segments. Furthermore, we show that undifferentiated hESCs also adhere to Matrigel-coated microcarriers and are amenable to directed RPE differentiation. The capacity to support hPSC-RPE cell cultures using microcarriers enables efficient large-scale production of therapeutic RPE cells sufficient to meet the treatment demands of a large AMD patient population.

1 February 2016 in Frontiers in Biology
Verified
Journal Article
Closed access
PDF file
JBJeffrey K. Bailey
Jeffrey K. Bailey
ZMZach Ma
Zach Ma

13 July 2024 in Cells
Verified
Journal Article
Open access
PDF file
JBJeffrey K. Bailey
Jeffrey K. Bailey
ZMZach Ma
Zach Ma
DCDennis O. Clegg
Dennis O. Clegg
The chromatin-associated protein WDR5 has been widely studied due to its role in histone modification and its potential as a pharmacological target for the treatment of cancer. In humans, the protein with highest sequence homology to WDR5 is encoded by the retrogene WDR5B, which remains unexplored. Here, we used CRISPR-Cas9 genome editing to generate WDR5B knockout and WDR5B-FLAG knock-in cell lines for further characterization. In contrast to WDR5, WDR5B exhibits low expression in pluripotent cells and is upregulated upon neural differentiation. Loss or shRNA depletion of WDR5B impairs cell growth and increases the fraction of non-viable cells in proliferating retinal pigment epithelial (RPE) cultures. CUT&RUN chromatin profiling in RPE and neural progenitors indicates minimal WDR5B enrichment at established WDR5 binding sites. These results suggest that WDR5 and WDR5B exhibit several divergent biological properties despite sharing a high degree of sequence homology.